The Role of Tumor Budding in Early‐Stage Laryngeal Cancer Treatment Selection
The Laryngoscope · 2025
DOI: 10.1002/lary.32218 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Mehmet Birinci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Recep Tayyip Erdogan University Faculty of Medicine, Rize, Türkiye. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Laryngeal cancer is a prevalent malignant neoplasm, with early‐stage glottic tumors treated with surgery or radiotherapy. Radioresistance significantly complicates treatment, highlighting the necessity for early detection methods. This study aimed to evaluate the relationship between tumor budding and radiotherapy outcomes in affected patients.
Methods
This investigation encompassed patients diagnosed with early‐stage squamous cell carcinoma of the glottic larynx who received radiotherapy and had a minimum follow‐up of 1 year. Pathological specimens collected at diagnosis were reassessed for tumor budding. The data were analyzed to determine the best cut‐off value for tumor budding to predict radioresistance and differences in survival based on tumor budding cut‐off value.
Results
The study cohort comprised 49 patients who met the pre‐established criteria. The radioresistant group comprised 14 patients. All except one patient were male (mean age: 64 years). The best cut‐off value for tumor budding was determined as 2. Patients categorized into high risk (tumor budding ≥ 2) had a significantly higher chance of radiotherapy failure than those with low risk (tumor budding < 2, AUC = 0.696; p = 0.034; sensitivity = 78.6%; specificity = 62.9%). The high risk group also had a significantly reduced 5‐year disease‐free survival compared to the low risk group ( p = 0.008). Overall survival was similar.
Conclusion
The prognosis for early‐stage glottic laryngeal cancer is generally favorable, yet a standardized risk stratification tool for treatment selection remains lacking. Tumor budding assessment in routine histopathology could help identify patients at higher risk of recurrence, guiding decisions on radiotherapy intensity and post‐treatment surveillance. Integrating tumor budding into clinical practice may support more personalized treatment strategies, ultimately improving patient outcomes. Level of Evidence: 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Recep Tayyip Erdogan University Faculty of Medicine, Rize, Türkiye.
- Department of Otorhinolaryngology, Akçaabat Haçkalı Baba State Hospital, Trabzon, Türkiye.
- Department of Pathology, Recep Tayyip Erdogan University Faculty of Medicine, Rize, Türkiye.
- Department of Medical Biochemistry, Recep Tayyip Erdogan University Training and Research Hospital, Rize, Türkiye.
ORCID-Profile: Mehmet Birinci, Oğuz Gül, Oğuzhan Okcu, Tuğba Yemiş, Bayram Şen, Metin Çeliker, Çiğdem Öztürk, Özlem Çelebi Erdivanlı
Zitieren
APA
Birinci, M., Gül, O., Okcu, O., Yemiş, T., Şen, B., Çeliker, M., Öztürk, Ç., & Erdivanlı, Ö. Ç. (2025). The Role of Tumor Budding in Early‐Stage Laryngeal Cancer Treatment Selection. The Laryngoscope. https://doi.org/10.1002/lary.32218
Vancouver
Birinci M, Gül O, Okcu O, Yemiş T, Şen B, Çeliker M, et al. The Role of Tumor Budding in Early‐Stage Laryngeal Cancer Treatment Selection. The Laryngoscope. 2025. doi:10.1002/lary.32218
BibTeX
@article{Birinci2025,
author = {Birinci, Mehmet and Gül, Oğuz and Okcu, Oğuzhan and Yemiş, Tuğba and Şen, Bayram and Çeliker, Metin and Öztürk, Çiğdem and Erdivanlı, Özlem Çelebi},
title = {The Role of Tumor Budding in Early‐Stage Laryngeal Cancer Treatment Selection},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32218}
}
EUVIMED